Radiaton pneumonitis with the combination of irinotecan and carboplatin concomitantly with radiation for stage III non-small cell lung cancer

7582 Background: We evaluated the efficacy and safety of carboplatin (C) and irinotecan (I) concomitantly with radiation therapy followed by docetaxel (D) in patients (pts) with stages IIIA/B NSCLC. Methods: We enrolled 32 pts. The daily dose of radiation was 1.8 Gy, 5 days a week for 5 weeks, 25 fractions, (45 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV. After 45 Gy, the primary tumor and involved nodal metastasis (secondary planning target volume: SPTV) was boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose given was 63 Gy in 35 fractions over 7 weeks. C was given with an AUC=2 and I was given at 30mg/m2 both of them weekly for 7 weeks. D was given at 75mg/m2 as consolidation chemotherapy for 3 cycles. Results: Median age was 55 years (range: 42–78), most pts were females (74%), 57% were Caucasian and 57% were Hispanic. The most common histologies were poorly differentiated and squamous cell carcinomas. Half of the pts were stage IIIB. The overall response...